secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXAGEN INC. (XGN)
CIK:        0001274737
Form:       8-K
Filed at:   2023-03-20T23:59:59+00:00
Accession:  0001274737-23-000017
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exagen Q4 net loss $14.4M on $5.5M goodwill impairment; Q1 revenue guidance raised to $9.2-9.7M
--------------------------------------------------------------------------------

- Record 135,210 AVISE CTD tests in 2022; 33,819 in Q4; cumulative ~750,000 since 2012 launch.
- Q4 revenue $12.8M (+0.8% YoY); gross margin fell to 50.9% from 61.1% on inflation and mix.
- Full-year 2022 net loss $47.4M vs $26.9M in 2021; operating expenses rose to $91.6M.
- New CEO John Aballi joined Q4 2022; strategy focuses on reducing cash burn and reaching profitability.
- Q1 2023 revenue guidance raised to $9.2-9.7M from prior $8.2-9.2M range.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1274737/000127473723000017/0001274737-23-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1274737/000127473723000017/exdx-20230320.htm
  HTML page:      https://secwatch.observer/filing/0001274737-23-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer